


PATENT
ATTORNEY DOCKET NO. 50304/072001

Certificate of Mailing	
Date of Deposit: <u>August 3, 2005</u>	Label Number: <u>EV558626605US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Josh Wheeler</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DEBYSER et al.	Art Unit:	To Be Assigned
Serial No.:	10/529,508	Examiner:	To Be Assigned
Filed:	March 28, 2005	Customer No.:	21559
Title:	INTEGRASE COFACTOR		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821

In Reply to the Notification to Comply with Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures that was mailed in connection with the above-captioned application on July 6, 2005, and as required by 37 C.F.R. §§ 1.821 through 1.825, enclosed is a Sequence Listing consisting of 5 pages. As set forth in the concurrently filed Preliminary Amendment, this sequence listing is to be added to the end of the application.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the Sequence Listing, and each sequence in the Sequence Listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 3 August 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045